What Does Abcam’s New Buy Mean for Oncology and Gene Editing Research?

Abcam, the life sciences giant makes a strategic purchase in its pursuit to expand research technology.

Abcam is a giant in the world of cutting-edge biological research tools.

They recently made a major deal with Applied StemCell (ASC). ASC has an important role in pharmaceutical research as a developer of gene editing technology.

Abcam bought a large portfolio of research tools from ASC. The portfolio contains mountains of clinical data and reference materials that will help scientists target cancer mutations. Both companies are excited about the transaction.

They hope that Abcam’s expansion of ASC’s technology will lead to fruitful clinical trials in the future.

 

gene-editing3 Key Points:
1. This deal involves two major players in the world of biological research tools, Abcam and Applied StemCell.
2. Abcam’s purchase includes multiple cell lines as well as reference tools that scientists can use in a clinical trial.
3. The materials will be used to collect clinical data about the use of gene editing technology in cancer treatment.

“As recognised industry leaders in the provision of biologic reagents and tools, Abcam is ideally placed to provide expert support to our global user-base.”

 

Article Source: http://bit.ly/3bKQMSj
Image Source: http://bit.ly/2SAQupJ, http://bit.ly/38vNy37

#ClinicalTrials #Pharmaceutical #GeneEditing

 

p.s.: See Breaking News in Clinical Trials! Get new Article Summaries delivered to your inbox, free. Click here to learn more.

Latest news

ACTide by Nubilaria against COVID-19

DECEIVER trial for COVID-19 related ARDS intensive care

Read more
Nubilaria ACTide @ Medical device trials

Medical Device Trials – Virtual Experience

Read more
Nubilaria ACTide @ Direct to Patient digital experience

Direct-to-Patient and Virtual Clinical Trials – Digital Experience

Read more

Want more information about our solutions?
Contact us today.

I've read and accept theTerms and Conditions and the Privacy Policy
   I would like to receive information about products and services via traditional mail, telephone, email and automated communication systems